35
Participants
Start Date
March 26, 2013
Primary Completion Date
May 8, 2018
Study Completion Date
May 8, 2018
GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
NIH Clinical Center, Bethesda
Lead Sponsor
National Cancer Institute (NCI)
NIH
NantCell, Inc.
INDUSTRY